Stock analysisUpdated Nov 20, 2026

Novo Nordisk (NVO): the bull case and the bear case

Novo Nordisk is a Danish pharmaceutical company best known for diabetes treatments and obesity medicines such as semaglutide-based drugs, which are sold worldwide and have driven much of its recent growth. NVO shares last traded at 38.10 USD, down 2.0% on the most recent day, 3.4% over the past month, 15.2% over six months and 19.9% over the past year, and they sit 40.4% below their 52-week high. The recent headlines are a mix of cautious optimism, with one piece arguing a return to growth may be near and another saying the worst may be behind the company, alongside rising competition from Eli Lilly and Amgen.

Price

38.11 USD

Last day

-2.0%

1 month

-3.4%

6 months

-15.2%

1 year

-19.9%

From 52-week high

-40.4%

The bull case for NVO

Strong position in obesity and diabetes

Novo Nordisk is one of the leading makers of GLP-1 based medicines, a fast-growing category with large global demand. Its established products and manufacturing scale give it a meaningful head start in these markets.

Analysts see a possible turnaround

Recent commentary, such as the headline suggesting a return to growth may be near, points to the idea that the recent slump could be temporary. If sales growth resumes, the share price could respond to improved expectations.

Shares trade well below recent highs

With the stock 40.4% below its 52-week high, some investors may see the lower price as a reason to look more closely at the company. Lower prices can also mean the market has already priced in a good deal of bad news.

The bear case for NVO

Intense competition in weight-loss drugs

Eli Lilly and Amgen, which has advanced its MariTide candidate into Phase 3 trials, are pursuing similar and next-generation treatments. Rising competition could pressure Novo Nordisk's prices and market share.

Share price has been falling for a year

NVO is down 19.9% over one year and 15.2% over six months, showing a sustained downward trend. Momentum has been negative, and a falling price can continue for longer than many investors expect.

Pricing and policy pressure

Drug prices, insurance coverage decisions and government policies in the US and elsewhere can reduce what companies earn from their medicines. Changes in these areas could weigh on revenue and margins.

What to watch next

Latest NVO headlines

Get alerts when NVO moves, with the reason why

Ask Vant AI anything about Novo Nordisk, get the daily brief, and see 5 AI picks every morning, tracked in public. Free on iPhone.

Get Vantrixa free

NVO questions

Is Novo Nordisk stock a good buy right now?

Whether NVO suits you depends on your goals, time horizon and tolerance for risk. The bull case centres on its strong obesity and diabetes franchise and a possible return to growth, while the bear case highlights intense competition, a steady share price decline and pricing pressure. Weighing both sides against your own situation is the best way to decide.

Why is NVO moving?

The stock is down 19.9% over one year and 15.2% over six months, with a 2.0% drop on the latest day. Recent headlines discuss both a possible return to growth and the risk that competitors like Eli Lilly and Amgen are gaining ground in the same market.

What are the biggest risks for Novo Nordisk?

The main risks are competition from rival obesity and diabetes drugs, which could erode sales and pricing. Regulatory, pricing and reimbursement changes in key markets could also reduce revenue.

More analysis

Information and education only, not financial advice. Vantrixa is not a broker. Figures come from public market data and may be delayed; past performance does not guarantee future results.